The global hyperlipidemia drug market is estimated to grow at a CAGR of around 2% during the forecast period. Growing sedentary lifestyle and high fat and dairy food consumption is contributing to the demand for hyperlipidemia drug. In addition, growing obesity and growing number of patients with heart disease or diabetes are also propelling the growth of the global hyperlipidemia drug market. Side effects of hyperlipidemia drugs are restraining the growth of the global hyperlipidemia drug market. Hyperlipidemia is a medical term for abnormally high levels of fats (lipids) in the blood.
Get Free Sample link @ https://www.omrglobal.com/request-sample/hyperlipidemia-drug-market
The two major types of lipids found in the blood are triglycerides and cholesterol. Triglycerides are made when the body stores the extra calories it doesn’t need for energy. They also come directly from the diet in foods such as red meat and whole-fat dairy. A diet high in refined sugar, fructose, and alcohol raise triglycerides. Cholesterol is produced naturally in the liver. Similar to triglycerides, cholesterol is also found in fatty foods like eggs, red meat, and cheese. Hyperlipidemia is more commonly known as high cholesterol. Although high cholesterol can be inherited, it’s more often the result of unhealthy lifestyle choices.
A full report of Global Hyperlipidemia Drug Market available @ https://www.omrglobal.com/industry-reports/hyperlipidemia-drug-market
- Market Coverage
- Market number available for – 2022-2028
- Base year- 2021
- Forecast period- 2022-2028
- Segment Covered- By Source, By Product Type, By Applications
- Competitive Landscape- Archer Daniels Midland Co., Ingredion Inc., Kerry Group Plc, Cargill Inc., and others
Market Segmentation
Global Hyperlipidemia Drug Market by Drug Class
- HMG-CoA Reductase Inhibitors (Statins)
- PCSK9 Inhibitors
- Cholesterol Absorption Inhibitors
- Fabric Acid Derivatives (Fibrates)
- Niacin (Nicotinic Acid)
- Bile Acid Sequestrants(BAS)
- Combination Therapy
- Others
Regional Analysis
- North America
- United States
- Canada
- Europe
- UK
- Germany
- Italy
- Spain
- France
- Rest of Europe
- Asia-Pacific
- China
- India
- Japan
- Rest of Asia-Pacific
- Rest of the World
Company Profiles
- Abbott Laboratories
- Amgen, Inc.
- AstraZeneca PLC
- Bristol-Myers Squibb Co.
- Daiichi Sankyo Co., Ltd.
- Reddy’s Laboratories, Ltd.
- GlaxoSmithKline PLC
- Ionis Pharmaceuticals, Inc.
- Merck & Co., Inc.
- Mylan N.V.
- Novartis AG
- Pfizer, Inc.
- Sanofi-Aventis S.A.
- Sun Pharmaceutical Industries, Ltd.
- Teva Pharmaceutical Industries, Ltd.
The Report Covers
- Market value data analysis of 2018 and forecast to 2025.
- Annualized market revenues ($ million) for each market segment.
- Country-wise analysis of major geographical regions.
- Key companies operating in the global hyperlipidemia drug market. Based on the availability of data, information related to pipeline products, and relevant news is also available in the report.
- Analysis of business strategies by identifying the key market segments positioned for strong growth in the future.
- Analysis of market-entry and market expansion strategies.
- Competitive strategies by identifying ‘who-stands-where’ in the market.
For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/hyperlipidemia-drug-market
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 780-304-0404
